Previous 10 | Next 10 |
DTIL has been lagging due to poor durability data. The company stock has been lagging due to market indifference. I see no prospects here. For further details see: Precision Bio: Another CAR-T Laggard With No Solid Prospects
By selling its only growth asset, Viatris has turned out to be a cigar butt investment that still has many puffs left in it due to its strong free cash flow. Debt remains a concern, but the company continues to deleverage thanks to its strong free cash flow and has accelerated the pro...
A phase 2a study using Lomecel-B for Alzheimer's Disease is currently enrolling patients; a prior phase 1 study established excellent safety profile with some efficacy. The global Alzheimer's Disease market could reach $25 billion by 2027. Lomecel-B has several shots on goal; besi...
FBT doesn’t pay any dividend and had a negative price growth over the short term. Barring the inverse funds, all other biotechnology ETFs had a high negative growth over the past 12 months. FBT’s price multiples are around category average, and current price is quite...
KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later. Until then, I see little upside for the stock. For further details see: Karyopharm: Another 2 Year Wait For Data
MorphoSys stock has taken a huge hit since its Constellation buyout. The company has staked an entire existing revenue stream for a development stage asset. The market hasn't taken this kindly. For further details see: MorphoSys May Not Recover From Adventurous Constella...
We circle back on OncoCyte Corp. for the first time in just over one year. This oncology diagnostic concern has several new products it plans to launch on the near-term horizon. A beneficial owner was a heavy buyer of a recent secondary offering. A full investment analysis is prov...
AMTI is developing a medicine for pouchitis. The company is undercovered and maybe undervalued. Its drug delivery platform is its key asset. For further details see: Applied Molecular: Interesting Drug Delivery Approach For The GI Tract
Top line results or TLR from the IMerge phase 3 trial will be out by January 2023. This is a confirmatory trial that may lead to an NDA, if successful. The CEO says he can't wait. Guess what, neither can we. For further details see: Geron: TLR Is 10 Months Away
During the last Fed rate raising cycle, it took the Federal Reserve five years to raise the fed funds rate to 2.50%. The Fed kept rates far too low for far too long and now we are dealing with the consequences. Both fiscal and monetary policy have been highly inflationary, and we are ...
News, Short Squeeze, Breakout and More Instantly...
iShares Biotechnology ETF Company Name:
IBB Stock Symbol:
NASDAQ Market:
2024-07-19 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 22:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...